Indian drugmaker Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to market an oral suspension form of Warner Chilcott's Duricef antibiotic, the Bombay Stock Exchange said on Thursday.
Warner Chilcott is the US unit of Northern Irish specialty drug maker Galen Holdings.
Ranbaxy has received approval for the 125 mg/5 ml, 250 mg/5 ml and 500 mg/5 ml strengths of the suspension drug.
It said the suspension product, which had sales of $16.7 million in 2002, will be launched in the United States in June.
